Roche studies new future for Nutley complex; Neuralstem touts PhI OK for lead candidate;

 @FierceBiotech: In case you missed it last week: Looks like an exciting year from JPM13. Slideshow | Follow @FierceBiotech

@JohnCFierce: Activists cry havoc, let slip the dogs of war on AstraZeneca. News | Follow @JohnCFierce

@RyanMFierce: PatientsLikeMe tackles extremely rare genetic disease. Item | Follow @RyanMFierce

> As operations wind down for Roche's ($RHHBY) sprawling campus in Nutley, NJ, company officials and local economic development groups are focusing on opening a new chapter for the facilities. Report

> Shares of Neuralstem ($CUR) were buoyed this morning by the news that it won a regulatory green light for a Phase I study of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. Release

> New research indicates that a molecular switch could play a major role in tumor suppression. Release

Pharma News

@FiercePharma: Zytiga wins European approval for earlier use. FDA did the same in December. Could be big for Janssen/J&J. More | Follow @FiercePharma

 @AlisonBFierce: Widespread flu outbreak gives vaccine manufacturers a shot in the arm. News | Follow @AlisonBFierce

> Generic Reglan user can sue Pfizer for damages. Article

> Brand-new AbbVie reveals second Synthroid recall. News

> India to hit Roche, BMS with compulsory licenses on 3 cancer drugs. Story

Medical Device News

 @FierceMedDev: Experts: Odds of device tax repeal close to zero. Item | Follow @FierceMedDev

@MarkHFierce: Covidien begins post-approval study for stroke treatment device. More | Follow @MarkHFierce

 @DamianFierce: Last thing from JPM13: Talking Chinese outsourcing with Vertex, Merck, MedImmune and WuXi. Story | Follow @DamianFierce

> Zimmer shutters Austin plant, plots Twin Cities move. News

> J&J's other hip device lands it back in court. Story

Biotech IT News

> How 'open' will Big Pharma get to treat R&D ills? Item

> Computer game rewards players for shirking flu shots. Report

> Elsevier snaps up drug R&D software company. Article

> Illumina, Life Tech trumpet startup efforts in clinical genomics. News

CRO News

> Report: Indian drug-related trial deaths rose in 2012. Report

> goBalto inks deal with INC for trial software. Article

> Catalent breathes $20M into inhalant business. News

> GVK partners with Onconova on cancer drugs. Story

> Parexel chief named ACRO chairman. Item

And Finally… A new study finds that children who regularly indulge themselves with fast food suffer higher rates of asthma and eczema. Story

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.